Evidence map›Paper›PMID 19321602›Full record

ArticleJournal of virology2009

Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.

Zhen-yong Keck, Sophia H Li, Jinming Xia, Thomas von Hahn, Peter Balfe, Jane A McKeating, Jeroen Witteveldt, Arvind H Patel, Harvey Alter, Charles M Rice and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 104 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Zhen-yong KeckDepartment of Pathology, Stanford University, Stanford, California 94305, USA.
Sophia H Li
Jinming Xia
Thomas von Hahn
Peter Balfe
Jane A McKeating
Jeroen Witteveldt
Arvind H Patel
Harvey Alter
Charles M Rice
Steven K H Foung
Stanford University · USNIHR Birmingham Biomedical Research Centre · GBRockefeller University · USUniversity of Glasgow · GB

Funding

Identification and characterization of cellular factors involved in HCV entryR01AI072613 · NIAID · ROCKEFELLER UNIVERSITY · PI RICE, CHARLES M · 2007 to 2016
$4.7M
Neutralizing Antibodies to Hepatitis CR01HL079381 · NHLBI · STANFORD UNIVERSITY · PI FOUNG, STEVEN · 2004 to 2008
$2.8M
A Prospective Study Of Anti-hepatitis C Virus Positive Blood DonorsZIACL002068 · CLC · CLINICAL CENTER · PI DE GIORGI, VALERIA · 2009 to 2025
$0k
Viral And Immune Factors That Influence Recovery Or Progression Of Hepatitis CZIACL002078 · CLC · CLINICAL CENTER · PI DE GIORGI, VALERIA · 2009 to 2025
$0k
Medical Research Council G0400802Medical Research Council G0801976Medical Research Council MC_U130184144NHLBI NIH HHS HL07938NHLBI NIH HHS R01 HL079381NIAID NIH HHS AI072613NIAID NIH HHS N01 AI040034NIAID NIH HHS R01 AI072613
6 · The paper itself

Abstract

Broadly neutralizing antibodies are commonly present in the sera of patients with chronic hepatitis C virus (HCV) infection. To elucidate possible mechanisms of virus escape from these antibodies, retrovirus particles pseudotyped with HCV glycoproteins (HCVpp) isolated from sequential samples collected over a 26-year period from a chronically infected patient, H, were used to characterize the neutralization potential and binding affinity of a panel of anti-HCV E2 human monoclonal antibodies (HMAbs). Moreover, AP33, a neutralizing murine monoclonal antibody (MAb) to a linear epitope in E2, was also tested against selected variants. The HMAbs used were previously shown to broadly neutralize HCV and to recognize a cluster of highly immunogenic overlapping epitopes, designated domain B, containing residues that are also critical for binding of viral E2 glycoprotein to CD81, a receptor essential for virus entry. Escape variants were observed at different time points with some of the HMAbs. Other HMAbs neutralized all variants except for the isolate 02.E10, obtained in 2002, which was also resistant to MAb AP33. The 02.E10 HCVpp that have reduced binding affinities for all antibodies and for CD81 also showed reduced infectivity. Comparison of the 02.E10 nucleotide sequence with that of the strain H-derived consensus variant, H77c, revealed the former to have two mutations in E2, S501N and V506A, located outside the known CD81 binding sites. Substitution A506V in 02.E10 HCVpp restored binding to CD81, but its antibody neutralization sensitivity was only partially restored. Double substitutions comprising N501S and A506V synergistically restored 02.E10 HCVpp infectivity. Other mutations that are not part of the antibody binding epitope in the context of N501S and A506V were able to completely restore neutralization sensitivity. These findings showed that some nonlinear overlapping epitopes are more essential than others for viral fitness and consequently are more invariant during earlier years of chronic infection. Further, the ability of the 02.E10 consensus variant to escape neutralization by the tested antibodies could be a new mechanism of virus escape from immune containment. Mutations that are outside receptor binding sites resulted in structural changes leading to complete escape from domain B neutralizing antibodies, while simultaneously compromising viral fitness by reducing binding to CD81.

Indexed as

Amino Acid SubstitutionAntibodies, MonoclonalAntibody AffinityAntigens, CDBinding SitesCell LineEpitopesHepacivirusHepatitis CHepatitis C AntibodiesHumansMutagenesis, Site-DirectedMutationNeutralization TestsSequence Analysis, ProteinTetraspanin 28Antibodies, MonoclonalAntigens, CDCD81 protein, humanEpitopesglycoprotein E2, Hepatitis C virusHepatitis C AntibodiesTetraspanin 28Viral Envelope Proteins

Identifiers

PMID19321602
PMCPMC2687388
OpenAlexW2117105620

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.